This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany | MicrobiomeTrials
← Back to trials NCT07549516
A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany Recruiting OBSERVATIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-04-17Est. Completion: 2030-09-30
Enrollment target: 380 participantsLocations Novartis Investigative Site, Baden-Baden, Baden-Wurttemberg, Germany Novartis Investigative Site, Heidenheim, Baden-Wurttemberg, Germany Novartis Investigative Site, Schwäbisch Hall, Baden-Wurttemberg, Germany Novartis Investigative Site, Aschaffenburg, Bavaria, Germany Novartis Investigative Site, Augsburg, Bavaria, Germany Novartis Investigative Site, Donauwörth, Bavaria, Germany Novartis Investigative Site, Herrsching am Ammersee, Bavaria, Germany Novartis Investigative Site, Kempten (Allgäu), Bavaria, Germany Novartis Investigative Site, Landsberg am Lech, Bavaria, Germany Novartis Investigative Site, Munich, Bavaria, Germany Novartis Investigative Site, Regensburg, Bavaria, Germany Novartis Investigative Site, Bremerhaven, Free Hanseatic City of Bremen, Germany Novartis Investigative Site, Kassel, Hesse, Germany Novartis Investigative Site, Offenbach, Hesse, Germany Novartis Investigative Site, Rotenburg (Wümme), Lower Saxony, Germany Novartis Investigative Site, Twistringen, Lower Saxony, Germany Other microbiome trials you might be interested in Malignancy, Hematologic Neoplasms, Hematologic Neoplasms, Hematopoietic Blood Cancer Hematological Neoplasms Hematopoietic Malignancies Dysmyelopoietic Syndromes Hematopoetic Myelodysplasia Myeloid Leukemia, Acute Nonlymphoblastic Leukemia, Acute Leukemia, Lymphocytic, Acute
Background:
Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RA…
Bethesda, United States Est. completion Apr 30, 2029
Novartis Investigative Site, Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site, Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site, Solingen, North Rhine-Westphalia, Germany
Novartis Investigative Site, Wesel, North Rhine-Westphalia, Germany
Novartis Investigative Site, Zittau, Saxony, Germany
Novartis Investigative Site, Merseburg, Saxony-Anhalt, Germany
Novartis Investigative Site, Oldenburg in Holstein, Schleswig-Holstein, Germany
Novartis Investigative Site, Saalfeld, Thuringia, Germany
Novartis Investigative Site, Bad Friedrichshall, Germany
Novartis Investigative Site, Bad Liebenwerda, Germany
Novartis Investigative Site, Berlin, Germany
Novartis Investigative Site, Bremerhaven, Germany
Novartis Investigative Site, Buchholz Nordheide, Germany
Novartis Investigative Site, Cottbus, Germany
Novartis Investigative Site, Detmold, Germany
Novartis Investigative Site, Dorfen, Germany
Novartis Investigative Site, Dortmund, Germany
Novartis Investigative Site, Dresden, Germany
Novartis Investigative Site, Düren, Germany
Novartis Investigative Site, Erfurt, Germany
Novartis Investigative Site, Göttingen, Germany
Novartis Investigative Site, Hanover, Germany
Novartis Investigative Site, Hanover, Germany
Novartis Investigative Site, Hildesheim, Germany
Novartis Investigative Site, Kiel, Germany
Novartis Investigative Site, Leverkusen, Germany
Novartis Investigative Site, Mutlangen, Germany
Novartis Investigative Site, Naunhof, Germany
Novartis Investigative Site, Neuss, Germany
Novartis Investigative Site, Offenburg, Germany
Novartis Investigative Site, Oldenburg, Germany
Novartis Investigative Site, Parchim, Germany
Novartis Investigative Site, Potsdam, Germany
Novartis Investigative Site, Potsdam, Germany
Novartis Investigative Site, Schorndorf, Germany
Novartis Investigative Site, Soest, Germany
Novartis Investigative Site, Stade, Germany
Novartis Investigative Site, Wetzlar, Germany Contact Novartis Pharmaceuticals
Phase 2
Recruiting
Chronic Myelogenous Leukemia Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
The aim of this study is to support development of asciminib in the pediatric population (1 to \< 18 years) with Ph+ CML…
New Brunswick, United States Est. completion Feb 23, 2033